M&A / Deals

Coultreon banks $125M to support testing of former Galapagos immune drug

BioPharma Dive

Backed by Novo Holdings, Regeneron s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.

Immunology & Inflammation

Read full story

pharminent April 28, 2026 (Last updated: April 29, 2026)

BioPharma Dive

Backed by Novo Holdings, Regeneron s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.

Immunology & Inflammation

Read full story

Related Stories

Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

Arcera and Fosun sign MoU for neuroscience innovation

Rocket to sell PRV for $180m to advance gene therapy pipeline

You May Have Missed

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

AZ, Amgen will pilot FDA’s real-time clinical trial plan

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’